Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of EIDD-2801 in Healthy Volunteers
NCT04392219Phase 1Completed
- Start
- Apr 2020
- Primary completion
- Aug 2020
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing EIDD-2801 with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events at 20 days. Started Apr 2020; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04392219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392219.